Can a new drug keep the Heart's beat steady? trial puts verducatib to the test

This Phase 1 trial is testing whether an experimental drug called verducatib affects the heart's electrical activity, specifically the QT interval, which is a measure of heart rhythm safety. Healthy adults aged 18 to 50 will receive multiple doses of verducatib, a placebo, or moxifloxacin (a drug known to affect the QT interval) to compare effects. The study uses ECG monitoring and blood samples to see if verducatib changes heart rhythm compared to placebo, with moxifloxacin serving as a reference to validate the methods.